Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, exercised and sold 10,983 shares for approximately $256,200 on November 26, 2025, reducing his direct holdings by roughly 74%. The sale occurred following the company's strong Q3 results with revenues up 17.4% year-over-year and raised full-year guidance. While exercise-and-sell transactions are common for stock compensation management, the magnitude of this stake reduction warrants investor attention despite the company's positive operational momentum.

Long-term study of AGAMREE in Duchenne muscular dystrophy patients reveals comparable effectiveness to standard corticosteroids, with significantly lower rates of vertebral fractures and better growth maintenance over five years.

Santhera Pharmaceuticals reported positive long-term data for AGAMREE, showing comparable effectiveness to standard corticosteroids in treating Duchenne Muscular Dystrophy, with improved safety profile and reduced side effects like growth suppression and vertebral fractures.

Catalyst Pharmaceuticals and SERB S.A. reached a settlement with Lupin Pharmaceuticals regarding patent litigation for FIRDAPSE, allowing Lupin to market a generic version starting February 2035, with ongoing litigation against Hetero still pending.

Santhera Pharmaceuticals will provide an update on the commercial progress of its drug AGAMREE for the treatment of Duchenne Muscular Dystrophy, as well as outline its strategic plans for further market expansion and diversification of its rare disease portfolio.

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst Pharmaceuticals (NASDAQ:CPRX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 3 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $28.43, along with a high estimate of $34.00 and a low estimate of $23.00. Marking an increase of 7.98%, the current average surpasses the previous average price target of $26.33. Analyzing Analyst Ratings: A Detailed Breakdown The perception of Catalyst Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Andrew Fein HC Wainwright & Co. Maintains Buy $26.00 $26.00 Andrew Fein HC Wainwright & Co. Raises Buy $26.00 $24.00 Leland Gershell Oppenheimer Maintains Outperform $29.00 $29.00 Charles Duncan Cantor Fitzgerald Maintains Overweight $34.00 - Charles Duncan Cantor Fitzgerald Maintains Overweight $34.00 - Samantha Semenkow Citigroup Announces Buy $27.00 - Jason Gerberry B of A Securities Announces Buy $23.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' ...Full story available on Benzinga.com

CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE® (amifampridine) for adults and pediatric patients weighing more than 45 kg from 80 mg to 100 mg for the treatment of Lambert-Eaton myasthenic syndrome (“LEMS”). The increased maximum daily dose offers healthcare providers and patients greater flexibility in treatment regimens for the management of LEMS.

CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming Jefferies Global Healthcare Conference 2024 on Wednesday, June 5, 2024, in New York.

These two healthcare stocks may be deeply undervalued.

In the last three months, 8 analysts have published ratings on Catalyst Pharmaceuticals (NASDAQ:CPRX), offering a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 4 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 3 0 0 0 3M Ago 2 1 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $28.88, along with a high estimate of $34.00 and a low estimate of $23.00. This upward trend is apparent, with the current average reflecting a 8.29% increase from the previous average price target of $26.67. Investigating Analyst Ratings: An Elaborate Study In examining recent analyst actions, we gain insights into how financial experts perceive Catalyst Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Andrew Fein HC Wainwright & Co. Raises Buy $26.00 $24.00 Leland Gershell Oppenheimer Maintains Outperform $29.00 $29.00 Charles Duncan Cantor Fitzgerald Maintains Overweight $34.00 - Charles Duncan Cantor Fitzgerald Maintains Overweight $34.00 - Samantha Semenkow Citigroup Announces Buy $27.00 - Jason Gerberry B of A Securities Announces Buy $23.00 - Charles Duncan Cantor Fitzgerald Raises Overweight $34.00 $27.00 Andrew Fein HC Wainwright & Co. Maintains Buy $24.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Catalyst Pharmaceuticals. This insight gives a ...Full story available on Benzinga.com

Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.